Rituxan and Cutaneous vasculitis - a phase IV clinical study of FDA data

Summary:

Cutaneous vasculitis is reported as a side effect among people who take Rituxan (rituximab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Humira, and have Polychondritis.

The phase IV clinical study analyzes which people have Cutaneous vasculitis when taking Rituxan. It is created by eHealthMe based on reports of 64,282 people who have side effects when taking Rituxan from the FDA, and is updated regularly.

What is Rituxan?

Rituxan has active ingredients of rituximab. It is often used in rheumatoid arthritis. eHealthMe is studying from 64,792 Rituxan users. Check the latest studies of Rituxan.

What is Cutaneous vasculitis?

Cutaneous vasculitis (an inflammatory process affecting the vessel wall that leads to its damage) is found to be associated with 243 drugs and 344 conditions by eHealthMe. Check the latest studies of Cutaneous vasculitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

64,282 people reported to have side effects when taking Rituxan.
Among them, 15 people (0.02%) have Cutaneous vasculitis.

Could Rituxan cause Cutaneous vasculitis?

Among these 15 people:

How long have people been on Rituxan when they have Cutaneous vasculitis? *

What is the gender of people who have Cutaneous vasculitis when taking Rituxan? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Cutaneous vasculitis when taking Rituxan? *

What are other drugs people take besides Rituxan? *

Humira: 11 people, 73.33%
Actemra: 9 people, 60.00%
Enbrel: 7 people, 46.67%
Prednisone: 7 people, 46.67%
Xeljanz: 5 people, 33.33%
Metformin: 4 people, 26.67%
Orencia: 4 people, 26.67%
Calcium: 4 people, 26.67%
Diphenhydramine Hydrochloride: 4 people, 26.67%
Methotrexate: 4 people, 26.67%

What are other side effects people have besides Cutaneous vasculitis? *

Drug Ineffective: 10 people, 66.67%
Pain: 6 people, 40.00%
Infection: 6 people, 40.00%
Pneumonia: 5 people, 33.33%
Gait Disturbance: 5 people, 33.33%
Red Blood Cell Sedimentation Rate Increased: 5 people, 33.33%
White Blood Cell Count Decreased: 4 people, 26.67%
Ear Pain: 4 people, 26.67%
Joint Swelling: 4 people, 26.67%
Joint Pain: 4 people, 26.67%

What are the existing conditions these people have? *

Polychondritis (progressive inflammation of cartilage and other connective tissue): 4 people, 26.67%
Vasculitis Necrotising (inflammation and damage to blood vessels): 3 people, 20.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 13.33%
Osteoporosis (bones weak and more likely to break): 1 person, 6.67%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 1 person, 6.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Rituxan and have Cutaneous vasculitis?

- Check whether Cutaneous vasculitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rituxan:

Rituxan (64,792 reports)

Browse all side effects of Rituxan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cutaneous vasculitis:

Cutaneous vasculitis (243 drugs)

Browse all the conditions that are associated with Cutaneous vasculitis:

Cutaneous vasculitis (344 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rituximab (the active ingredients of Rituxan) and Rituxan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.